Astellas expects to make a greater contribution to the  treatment of type 2 diabetes. In Japan, Astellas will co- promote Suglat with Kotobuki and MSD K.K. Besides the aforementioned mainstay products, quite a few  new products were launched in fiscal 2013, including the  functional dyspepsia treatment Acofide (on sale from June  2013), the transdermal hypertension medication Bisono  Tape, (on sale from September 2013), and the diarrhea- predominant irritable bowel syndrome treatment Irribow OD  Tablets (on sale from January 2014). Sales of the Lipitor product line, Gaster, Myslee and Seroquel  in fiscal 2013 were as follows. Sales of each of these prod- ucts declined due primarily to the impact of generic drugs. Sales of the Lipitor product line (hypercholesterolemia  treatment), which includes Caduet (combination drug con- taining Lipitor and a long-acting calcium antagonist),  declined by 11.6%, to ¥62.4 billion. In fiscal 2013, the  market for statins in Japan shrank 1.4% year on year to  approximately ¥264.0 billion. Sales of Gaster (treatment for peptic ulcers and gastritis)  declined 14.9% to ¥25.7 billion. In fiscal 2013, the peptic  ulcer and gastritis market for H2 receptor antagonists and  proton pump inhibitors expanded 1.9% to approximately  ¥320.0 billion. Sales of Myslee (insomnia treatment) decreased 12.6%  to ¥28.2 billion. In fiscal 2013, the market for drugs to treat  insomnia in Japan shrank 0.9% year on year, to approxi- mately ¥80.0 billion. Sales of Seroquel (schizophrenia treatment) decreased  31.2% to ¥19.6 billion. The Japanese market for anti- schizophrenic agents showed growth of 4.7% to  approximately ¥171.0 billion in fiscal 2013. Gross profit increased by ¥136.1 billion, or 20.2%, to  ¥809.3 billion, due to growing sales, as well as a decrease  in the cost of sales ratio. Cost of sales increased by ¥21.9 billion to ¥330.6 billion.  The cost of sales ratio fell 2.4 percentage points in fiscal  2013, to 29.0%, mainly due to changes in the product mix. Furthermore, in the U.S., approval was obtained in May  2013 for the additional indication of the first-line treatment  for people with metastatic non-small cell lung cancer  whose tumors have certain epidermal growth factor  receptor (EGFR) activating mutations as detected by an  FDA-approved test. In the U.S., we have been co-promoting Tarceva with  Genentech, Inc., with earnings split equally between  both companies. We also have a license agreement with  F. Hoffmann-La Roche Ltd in other countries, and receive  royalties based on sales. These revenues are recorded as  sales in the Americas. Tarceva-related revenues increased 1.4% to US$446 mil- lion on a U.S. dollar basis. When converted to yen, sales  increased 22.3%, to ¥44.7 billion. Total sales of Adenoscan and Lexiscan in the U.S. declined  by 3.5% to US$617 million on a U.S. dollar basis, mainly  due to the launch in September 2013 of generic products  for Adenoscan in the U.S. Lexiscan continued to show  growth, rising 2.2% to US$585 million. Total sales  increased 16.5% to ¥61.8 billion when converted to yen. Adenoscan/Lexiscan (Pharmacologic stress agent) Americas Other New Products Other Mainstay Products Tarceva (Lung and pancreatic cancer treatment) Cost of Sales, Gross Profit (¥ billion) 2013.3 2014.3 Sales ¥981.9 ¥1,139.9 Cost of sales 308.7 330.6 Cost of sales ratio (%) 31.4 29.0 Astellas Pharma Inc.  _ Annual Report 2014 92